Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Horizon Therapeutics
Pharma
Amgen's products from buyout of Horizon continue to struggle
While Amgen’s legacy products are thriving, those gained from the company’s 2023 buyout of Horizon are struggling, especially blockbuster Tepezza.
Kevin Dunleavy
May 2, 2025 8:18am
Amgen's 13-year CEO Robert Bradway gains 8% pay hike to $24.4M
Apr 14, 2025 3:50pm
Amgen's Uplizna expansion push bears fruit with rare disease nod
Apr 4, 2025 11:05am
Amgen reaps Horizon buyout rewards in Q3, preps biosim launches
Oct 31, 2024 7:50am
Amgen's Uplizna posts strong results in myasthenia gravis trial
Sep 25, 2024 11:37am
Roche regains reputation crown among rare disease patient groups
Aug 20, 2024 11:25am
